Zevra Therapeutics
ZVRA
36 hedge funds and large institutions have $17.8M invested in Zevra Therapeutics in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
10% less funds holding
Funds holding: 40 → 36 (-4)
39% less capital invested
Capital invested by funds: $29M → $17.8M (-$11.2M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.98M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$126K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$121K |
| 4 |
Bank of New York Mellon
New York
|
+$74.6K |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$62.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.72M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.17M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$740K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$650K |
| 5 |
SIM
Spark Investment Management
New York
|
-$135K |
ZVRA Hedge Fund Activity: Q4 2016 in Review
36 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2016, worth a combined $17.8M — down 39% from $29M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ZVRA and 2 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 13 added.
The largest buyer was DSC Advisors, adding an estimated $1.98M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.72M sold.
- 36 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2016, down from 40 in Q3 2016.
- Funds reported $17.8M of Zevra Therapeutics stock for Q4 2016, down 39% quarter-over-quarter.
- 2 funds opened new Zevra Therapeutics positions in Q4 2016 and 6 closed out, a net change of -4 holders.
- The largest Zevra Therapeutics buyer in Q4 2016 was DSC Advisors, an estimated $1.98M added.
- The largest Zevra Therapeutics seller in Q4 2016 was Point72 Asset Management, an estimated $1.72M sold.
Based on aggregated 13F filings for Q4 2016.